PEARL-I: A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of co-administration of ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as ombitasvir) in adults with chronic hepatitis C virus infection.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
This was a Phase 2, randomized, open-label, combination treatment study of the 2-DAA regimen (ABT-450 150 mg QD + ritonavir 100 mg QD + ABT-267 25 mg QD) in adult HCV GT1b-infected treatment-naïve and Pegylated-interferon/ribavirin (pegIFN/RBV) treatment-experienced participants without cirrhosis and with compensated cirrhosis, and in adult GT4-infected treatment-naïve and pegIFN/RBV treatment-experienced participants without cirrhosis. Treatment Group 5 was not open to enrollment, based on a protocol-specified interim review of results from the treatment-naïve GT4 Groups 1 and 4 that indicated higher sustained virologic response (SVR) rates among participants receiving the 2-DAA regimen with RBV. All other groups completed the study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Group 1 ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants |
Drug: ABT-450/r
Tablet; ABT-450; Capsule; ritonavir
Other Names:
Drug: ABT-267
Tablet
Other Names:
|
Experimental: Group 2 ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants |
Drug: ABT-450/r
Tablet; ABT-450; Capsule; ritonavir
Other Names:
Drug: ABT-267
Tablet
Other Names:
|
Experimental: Group 3 ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants |
Drug: ABT-450/r
Tablet; ABT-450; Capsule; ritonavir
Other Names:
Drug: ABT-267
Tablet
Other Names:
|
Experimental: Group 4 ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants |
Drug: ABT-450/r
Tablet; ABT-450; Capsule; ritonavir
Other Names:
Drug: ABT-267
Tablet
Other Names:
Drug: Ribavirin (RBV)
Tablet
|
Experimental: Group 5 ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-experienced, HCV GT4-infected participants |
Drug: ABT-450/r
Tablet; ABT-450; Capsule; ritonavir
Other Names:
Drug: ABT-267
Tablet
Other Names:
|
Experimental: Group 6 ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants |
Drug: ABT-450/r
Tablet; ABT-450; Capsule; ritonavir
Other Names:
Drug: ABT-267
Tablet
Other Names:
Drug: Ribavirin (RBV)
Tablet
|
Experimental: Group 7 ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis |
Drug: ABT-450/r
Tablet; ABT-450; Capsule; ritonavir
Other Names:
Drug: ABT-267
Tablet
Other Names:
|
Experimental: Group 8 ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis |
Drug: ABT-450/r
Tablet; ABT-450; Capsule; ritonavir
Other Names:
Drug: ABT-267
Tablet
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants in Each Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment [12 weeks after the last actual dose of study drug]
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [<LLOQ]) 12 weeks after the last dose of study drug.
Secondary Outcome Measures
- Percentage of Participants in Each Treatment Group With Sustained Virologic Response 24 Weeks Post-treatment [24 weeks after the last actual dose of study drug]
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [<LLOQ]) 24 weeks after the last dose of study drug.
- Percentage of Participants in Each Treatment Group With On-treatment Virologic Failure. [Baseline (Day 1), Day 3, and Treatment Weeks 1, 2 ,3 ,4, 6, 8, 10, and 12 for all participants and Treatment Weeks 16, 20 and 24 for Groups 7 and 8]
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment).
- Percentage of Participants in Each Treatment Group With Post-treatment Virologic Relapse. [Within 12 weeks after the last dose of study drug]
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment.
- Percentage of Participants in Each Treatment Group With Treatment-emergent Adverse Events [From the start of study drug administration until 30 days after the last dose,16 weeks for Groups 1, 2, 3, 4, and 6, and 28 weeks for Groups 7 and 8.]
Treatment-emergent adverse events were defined as any event that began or worsened in severity after initiation of study drug through 30 days after the last dose of study drug.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile
-
Subjects must meet one of the following:
-
Treatment-naive: Subject has never received antiviral treatment for hepatitis C infection OR
-
Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegIFN/RBV);
-
Body mass index (BMI) is ≥ 18 to < 38 kg/m^2.
-
Chronic HCV genotype 1b infection/with or without cirrhosis or HCV genotype 4 infection/without cirrhosis for at least 6 months prior to study screening.
-
Subject has plasma HCV RNA level > 10,000 IU/mL at Screening
Exclusion Criteria:
-
History of severe, life-threatening or other significant sensitivity to any drug.
-
Females who were pregnant or planned to become pregnant, or breastfeeding, or GT4-infected males whose partners were pregnant or planning to become pregnant within 7 months (or per local RBV label) after their last dose of study drug/RBV.
-
Recent history of drug or alcohol abuse that could preclude adherence to the protocol.
-
Positive test result for hepatitis B surface antigen or anti-Human Immunodeficiency Virus (HIV) antibodies.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- AbbVie (prior sponsor, Abbott)
Investigators
- Study Director: Nilou Mobashery, MD, AbbVie
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015 Jun 20;385(9986):2502-9. doi: 10.1016/S0140-6736(15)60159-3. Epub 2015 Mar 31.
- Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, Morillas RM, Hall C, Mobashery N, Redman R, Pilot-Matias T, Vilchez RA, Hézode C. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology. 2015 Oct;149(4):971-80.e1. doi: 10.1053/j.gastro.2015.07.001. Epub 2015 Jul 11.
- M13-393
- 2011-005762-38
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail | The study originally planned to enroll Group 5 (GT4 treatment-experienced, 2-DAA regimen for 12 weeks), but based on a protocol-specified interim review of results from the treatment-naïve GT4 Groups 1 and 4 that indicated higher SVR rates among participants receiving the 2-DAA regimen with RBV, Group 5 was not opened to enrollment. |
Arm/Group Title | Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 |
---|---|---|---|---|---|---|---|
Arm/Group Description | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis |
Period Title: Overall Study | |||||||
STARTED | 44 | 42 | 40 | 42 | 49 | 47 | 52 |
Completed Study Drug | 42 | 40 | 39 | 42 | 49 | 43 | 52 |
COMPLETED | 40 | 39 | 40 | 41 | 49 | 44 | 52 |
NOT COMPLETED | 4 | 3 | 0 | 1 | 0 | 3 | 0 |
Baseline Characteristics
Arm/Group Title | Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 | Total |
---|---|---|---|---|---|---|---|---|
Arm/Group Description | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis | Total of all reporting groups |
Overall Participants | 44 | 42 | 40 | 42 | 49 | 47 | 52 | 316 |
Age (years) [Mean (Standard Deviation) ] | ||||||||
Mean (Standard Deviation) [years] |
48.9
(10.0)
|
55.8
(6.9)
|
54.2
(9.6)
|
44.2
(12.7)
|
50.9
(10.1)
|
57.8
(7.1)
|
57.1
(6.0)
|
52.8
(10.1)
|
Sex: Female, Male (Count of Participants) | ||||||||
Female |
20
45.5%
|
17
40.5%
|
25
62.5%
|
14
33.3%
|
13
26.5%
|
24
51.1%
|
19
36.5%
|
132
41.8%
|
Male |
24
54.5%
|
25
59.5%
|
15
37.5%
|
28
66.7%
|
36
73.5%
|
23
48.9%
|
33
63.5%
|
184
58.2%
|
Outcome Measures
Title | Percentage of Participants in Each Treatment Group With Sustained Virologic Response 24 Weeks Post-treatment |
---|---|
Description | The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [<LLOQ]) 24 weeks after the last dose of study drug. |
Time Frame | 24 weeks after the last actual dose of study drug |
Outcome Measure Data
Analysis Population Description |
---|
All randomized participants who received at least 1 dose of study drug. |
Arm/Group Title | Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 |
---|---|---|---|---|---|---|---|
Arm/Group Description | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis |
Measure Participants | 44 | 42 | 40 | 42 | 49 | 47 | 52 |
Number (95% Confidence Interval) [Percentage of participants] |
86.4
196.4%
|
92.9
221.2%
|
90.0
225%
|
100.0
238.1%
|
100.0
204.1%
|
97.9
208.3%
|
98.1
188.7%
|
Title | Percentage of Participants in Each Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment |
---|---|
Description | The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [<LLOQ]) 12 weeks after the last dose of study drug. |
Time Frame | 12 weeks after the last actual dose of study drug |
Outcome Measure Data
Analysis Population Description |
---|
All randomized participants who received at least 1 dose of study drug. |
Arm/Group Title | Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 |
---|---|---|---|---|---|---|---|
Arm/Group Description | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis |
Measure Participants | 44 | 42 | 40 | 42 | 49 | 47 | 52 |
Number (95% Confidence Interval) [Percentage of participants] |
90.9
206.6%
|
95.2
226.7%
|
90.0
225%
|
100
238.1%
|
100
204.1%
|
97.9
208.3%
|
98.1
188.7%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Group 2, Group 3 |
---|---|---|
Comments | ||
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.381 |
Comments | ||
Method | Regression, Logistic | |
Comments | Treatment group, baseline log(subscript)10(subscript) HCV RNA level and Interleukin-28B (IL28B) genotype (CC or non-CC) were used as predictors |
Statistical Analysis 2
Statistical Analysis Overview | Comparison Group Selection | Group 1, Group 4 |
---|---|---|
Comments | ||
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.086 |
Comments | Difference in rates after adjusting for Interleukin-28 (IL28) genotype (CC or Non-CC) using stratum-adjusted Mantel-Haenszel proportions and continuity-corrected variances. | |
Method | Stratum-adjusted Mantel-Haenszel | |
Comments |
Title | Percentage of Participants in Each Treatment Group With On-treatment Virologic Failure. |
---|---|
Description | Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). |
Time Frame | Baseline (Day 1), Day 3, and Treatment Weeks 1, 2 ,3 ,4, 6, 8, 10, and 12 for all participants and Treatment Weeks 16, 20 and 24 for Groups 7 and 8 |
Outcome Measure Data
Analysis Population Description |
---|
All randomized participants who received at least 1 dose of study drug. |
Arm/Group Title | Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 |
---|---|---|---|---|---|---|---|
Arm/Group Description | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis |
Measure Participants | 44 | 42 | 40 | 42 | 49 | 47 | 52 |
Number (95% Confidence Interval) [Percentage of participants] |
2.3
5.2%
|
0
0%
|
2.5
6.3%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
Title | Percentage of Participants in Each Treatment Group With Post-treatment Virologic Relapse. |
---|---|
Description | Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. |
Time Frame | Within 12 weeks after the last dose of study drug |
Outcome Measure Data
Analysis Population Description |
---|
All randomized participants who received at least 1 dose of study drug and completed treatment with HCV RNA < LLOQ at the final treatment visit. |
Arm/Group Title | Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 |
---|---|---|---|---|---|---|---|
Arm/Group Description | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis |
Measure Participants | 42 | 40 | 39 | 42 | 49 | 44 | 52 |
Number (95% Confidence Interval) [Percentage of participants] |
4.8
10.9%
|
0
0%
|
7.7
19.3%
|
0
0%
|
0
0%
|
0
0%
|
1.9
3.7%
|
Title | Percentage of Participants in Each Treatment Group With Treatment-emergent Adverse Events |
---|---|
Description | Treatment-emergent adverse events were defined as any event that began or worsened in severity after initiation of study drug through 30 days after the last dose of study drug. |
Time Frame | From the start of study drug administration until 30 days after the last dose,16 weeks for Groups 1, 2, 3, 4, and 6, and 28 weeks for Groups 7 and 8. |
Outcome Measure Data
Analysis Population Description |
---|
All randomized participants who received at least 1 dose of study drug. |
Arm/Group Title | Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 |
---|---|---|---|---|---|---|---|
Arm/Group Description | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis |
Measure Participants | 44 | 42 | 40 | 42 | 49 | 47 | 52 |
Number [Percentage of participants] |
77.3
175.7%
|
73.8
175.7%
|
80.0
200%
|
88.1
209.8%
|
85.7
174.9%
|
85.1
181.1%
|
71.2
136.9%
|
Adverse Events
Time Frame | Adverse events were collected from the time of study drug administration until 30 days after the last dose, 16 weeks for Groups 1, 2, 3, 4, and 6, and 28 weeks for Groups 7 and 8. | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adverse Event Reporting Description | Serious adverse events were collected from the time of informed consent until the end of participation, up to 65 weeks. | |||||||||||||
Arm/Group Title | Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 | |||||||
Arm/Group Description | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants | ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/ RBV (pegIFN/RBV) treatment-experienced participants | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis | ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/ RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis | |||||||
All Cause Mortality |
||||||||||||||
Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 | ||||||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | |||||||
Serious Adverse Events |
||||||||||||||
Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 | ||||||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 2/44 (4.5%) | 1/42 (2.4%) | 1/40 (2.5%) | 0/42 (0%) | 0/49 (0%) | 3/47 (6.4%) | 2/52 (3.8%) | |||||||
Cardiac disorders | ||||||||||||||
ATRIAL FIBRILLATION | 1/44 (2.3%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 0/52 (0%) | |||||||
Gastrointestinal disorders | ||||||||||||||
OESOPHAGEAL VARICES HAEMORRHAGE | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 1/47 (2.1%) | 0/52 (0%) | |||||||
General disorders | ||||||||||||||
DEVICE EXTRUSION | 0/44 (0%) | 0/42 (0%) | 1/40 (2.5%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 0/52 (0%) | |||||||
Injury, poisoning and procedural complications | ||||||||||||||
CONTUSION | 1/44 (2.3%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 0/52 (0%) | |||||||
HUMERUS FRACTURE | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 1/52 (1.9%) | |||||||
ROAD TRAFFIC ACCIDENT | 1/44 (2.3%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 0/52 (0%) | |||||||
Investigations | ||||||||||||||
ALANINE AMINOTRANSFERASE INCREASED | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 1/47 (2.1%) | 0/52 (0%) | |||||||
ASPARTATE AMINOTRANSFERASE INCREASED | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 1/47 (2.1%) | 0/52 (0%) | |||||||
Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||||||||||
HEPATIC NEOPLASM | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 1/47 (2.1%) | 0/52 (0%) | |||||||
Nervous system disorders | ||||||||||||||
PARTIAL SEIZURES | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 1/52 (1.9%) | |||||||
Respiratory, thoracic and mediastinal disorders | ||||||||||||||
CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 0/44 (0%) | 1/42 (2.4%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 0/52 (0%) | |||||||
Vascular disorders | ||||||||||||||
PERIPHERAL ARTERY ANEURYSM | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 1/52 (1.9%) | |||||||
Other (Not Including Serious) Adverse Events |
||||||||||||||
Group 1 | Group 2 | Group 3 | Group 4 | Group 6 | Group 7 | Group 8 | ||||||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 30/44 (68.2%) | 24/42 (57.1%) | 26/40 (65%) | 32/42 (76.2%) | 38/49 (77.6%) | 34/47 (72.3%) | 33/52 (63.5%) | |||||||
Cardiac disorders | ||||||||||||||
TACHYCARDIA | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 1/42 (2.4%) | 0/49 (0%) | 3/47 (6.4%) | 0/52 (0%) | |||||||
Ear and labyrinth disorders | ||||||||||||||
VERTIGO | 1/44 (2.3%) | 3/42 (7.1%) | 1/40 (2.5%) | 0/42 (0%) | 0/49 (0%) | 2/47 (4.3%) | 0/52 (0%) | |||||||
Gastrointestinal disorders | ||||||||||||||
ABDOMINAL PAIN | 0/44 (0%) | 1/42 (2.4%) | 0/40 (0%) | 2/42 (4.8%) | 1/49 (2%) | 3/47 (6.4%) | 1/52 (1.9%) | |||||||
ABDOMINAL PAIN UPPER | 1/44 (2.3%) | 1/42 (2.4%) | 0/40 (0%) | 1/42 (2.4%) | 1/49 (2%) | 1/47 (2.1%) | 4/52 (7.7%) | |||||||
DIARRHOEA | 2/44 (4.5%) | 6/42 (14.3%) | 0/40 (0%) | 6/42 (14.3%) | 3/49 (6.1%) | 7/47 (14.9%) | 7/52 (13.5%) | |||||||
DYSPEPSIA | 1/44 (2.3%) | 0/42 (0%) | 0/40 (0%) | 2/42 (4.8%) | 4/49 (8.2%) | 0/47 (0%) | 0/52 (0%) | |||||||
FLATULENCE | 0/44 (0%) | 1/42 (2.4%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 1/47 (2.1%) | 3/52 (5.8%) | |||||||
NAUSEA | 4/44 (9.1%) | 8/42 (19%) | 0/40 (0%) | 7/42 (16.7%) | 6/49 (12.2%) | 5/47 (10.6%) | 5/52 (9.6%) | |||||||
VOMITING | 0/44 (0%) | 3/42 (7.1%) | 0/40 (0%) | 2/42 (4.8%) | 0/49 (0%) | 2/47 (4.3%) | 1/52 (1.9%) | |||||||
General disorders | ||||||||||||||
ASTHENIA | 11/44 (25%) | 3/42 (7.1%) | 2/40 (5%) | 10/42 (23.8%) | 16/49 (32.7%) | 10/47 (21.3%) | 7/52 (13.5%) | |||||||
FATIGUE | 3/44 (6.8%) | 6/42 (14.3%) | 0/40 (0%) | 5/42 (11.9%) | 9/49 (18.4%) | 4/47 (8.5%) | 6/52 (11.5%) | |||||||
INFLUENZA LIKE ILLNESS | 0/44 (0%) | 1/42 (2.4%) | 2/40 (5%) | 0/42 (0%) | 1/49 (2%) | 0/47 (0%) | 2/52 (3.8%) | |||||||
IRRITABILITY | 3/44 (6.8%) | 0/42 (0%) | 0/40 (0%) | 6/42 (14.3%) | 2/49 (4.1%) | 1/47 (2.1%) | 0/52 (0%) | |||||||
OEDEMA PERIPHERAL | 1/44 (2.3%) | 3/42 (7.1%) | 0/40 (0%) | 1/42 (2.4%) | 2/49 (4.1%) | 2/47 (4.3%) | 2/52 (3.8%) | |||||||
PYREXIA | 0/44 (0%) | 1/42 (2.4%) | 0/40 (0%) | 1/42 (2.4%) | 3/49 (6.1%) | 1/47 (2.1%) | 0/52 (0%) | |||||||
Infections and infestations | ||||||||||||||
BRONCHITIS | 1/44 (2.3%) | 0/42 (0%) | 1/40 (2.5%) | 1/42 (2.4%) | 2/49 (4.1%) | 3/47 (6.4%) | 1/52 (1.9%) | |||||||
GASTROENTERITIS | 0/44 (0%) | 0/42 (0%) | 2/40 (5%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 0/52 (0%) | |||||||
INFLUENZA | 1/44 (2.3%) | 1/42 (2.4%) | 2/40 (5%) | 0/42 (0%) | 2/49 (4.1%) | 1/47 (2.1%) | 2/52 (3.8%) | |||||||
NASOPHARYNGITIS | 2/44 (4.5%) | 1/42 (2.4%) | 2/40 (5%) | 2/42 (4.8%) | 6/49 (12.2%) | 4/47 (8.5%) | 4/52 (7.7%) | |||||||
RHINITIS | 1/44 (2.3%) | 0/42 (0%) | 0/40 (0%) | 0/42 (0%) | 3/49 (6.1%) | 0/47 (0%) | 0/52 (0%) | |||||||
UPPER RESPIRATORY TRACT INFECTION | 1/44 (2.3%) | 1/42 (2.4%) | 0/40 (0%) | 2/42 (4.8%) | 1/49 (2%) | 2/47 (4.3%) | 4/52 (7.7%) | |||||||
URINARY TRACT INFECTION | 3/44 (6.8%) | 2/42 (4.8%) | 2/40 (5%) | 1/42 (2.4%) | 2/49 (4.1%) | 2/47 (4.3%) | 1/52 (1.9%) | |||||||
Investigations | ||||||||||||||
BLOOD PRESSURE INCREASED | 0/44 (0%) | 0/42 (0%) | 2/40 (5%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 0/52 (0%) | |||||||
Metabolism and nutrition disorders | ||||||||||||||
DECREASED APPETITE | 1/44 (2.3%) | 1/42 (2.4%) | 0/40 (0%) | 1/42 (2.4%) | 3/49 (6.1%) | 2/47 (4.3%) | 1/52 (1.9%) | |||||||
HYPERGLYCAEMIA | 0/44 (0%) | 0/42 (0%) | 2/40 (5%) | 0/42 (0%) | 0/49 (0%) | 0/47 (0%) | 0/52 (0%) | |||||||
INCREASED APPETITE | 0/44 (0%) | 1/42 (2.4%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 3/47 (6.4%) | 0/52 (0%) | |||||||
Musculoskeletal and connective tissue disorders | ||||||||||||||
ARTHRALGIA | 0/44 (0%) | 1/42 (2.4%) | 0/40 (0%) | 2/42 (4.8%) | 1/49 (2%) | 4/47 (8.5%) | 0/52 (0%) | |||||||
BACK PAIN | 3/44 (6.8%) | 0/42 (0%) | 0/40 (0%) | 2/42 (4.8%) | 4/49 (8.2%) | 6/47 (12.8%) | 5/52 (9.6%) | |||||||
MYALGIA | 0/44 (0%) | 2/42 (4.8%) | 2/40 (5%) | 0/42 (0%) | 5/49 (10.2%) | 3/47 (6.4%) | 2/52 (3.8%) | |||||||
Nervous system disorders | ||||||||||||||
DIZZINESS | 1/44 (2.3%) | 1/42 (2.4%) | 3/40 (7.5%) | 0/42 (0%) | 3/49 (6.1%) | 0/47 (0%) | 1/52 (1.9%) | |||||||
HEADACHE | 13/44 (29.5%) | 14/42 (33.3%) | 10/40 (25%) | 14/42 (33.3%) | 14/49 (28.6%) | 9/47 (19.1%) | 10/52 (19.2%) | |||||||
Psychiatric disorders | ||||||||||||||
ANXIETY | 2/44 (4.5%) | 0/42 (0%) | 0/40 (0%) | 4/42 (9.5%) | 2/49 (4.1%) | 1/47 (2.1%) | 2/52 (3.8%) | |||||||
DEPRESSION | 1/44 (2.3%) | 0/42 (0%) | 0/40 (0%) | 1/42 (2.4%) | 3/49 (6.1%) | 1/47 (2.1%) | 1/52 (1.9%) | |||||||
INSOMNIA | 2/44 (4.5%) | 1/42 (2.4%) | 0/40 (0%) | 4/42 (9.5%) | 8/49 (16.3%) | 3/47 (6.4%) | 4/52 (7.7%) | |||||||
Respiratory, thoracic and mediastinal disorders | ||||||||||||||
COUGH | 0/44 (0%) | 2/42 (4.8%) | 2/40 (5%) | 2/42 (4.8%) | 4/49 (8.2%) | 3/47 (6.4%) | 5/52 (9.6%) | |||||||
DYSPNOEA EXERTIONAL | 0/44 (0%) | 0/42 (0%) | 0/40 (0%) | 2/42 (4.8%) | 3/49 (6.1%) | 0/47 (0%) | 0/52 (0%) | |||||||
EPISTAXIS | 1/44 (2.3%) | 0/42 (0%) | 2/40 (5%) | 0/42 (0%) | 1/49 (2%) | 0/47 (0%) | 1/52 (1.9%) | |||||||
RHINORRHOEA | 0/44 (0%) | 1/42 (2.4%) | 0/40 (0%) | 0/42 (0%) | 0/49 (0%) | 2/47 (4.3%) | 3/52 (5.8%) | |||||||
Skin and subcutaneous tissue disorders | ||||||||||||||
DRY SKIN | 0/44 (0%) | 7/42 (16.7%) | 0/40 (0%) | 0/42 (0%) | 3/49 (6.1%) | 1/47 (2.1%) | 0/52 (0%) | |||||||
PRURITUS | 2/44 (4.5%) | 6/42 (14.3%) | 0/40 (0%) | 1/42 (2.4%) | 5/49 (10.2%) | 8/47 (17%) | 9/52 (17.3%) | |||||||
Vascular disorders | ||||||||||||||
HYPERTENSION | 0/44 (0%) | 0/42 (0%) | 1/40 (2.5%) | 1/42 (2.4%) | 1/49 (2%) | 7/47 (14.9%) | 1/52 (1.9%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
Results Point of Contact
Name/Title | Global Medical Information |
---|---|
Organization | AbbVie (prior sponsor, Abbott) |
Phone | 800-633-9110 |
- M13-393
- 2011-005762-38